Exclusivity For Biologics, Drugs Should Be The Same After All, Grabowski Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Duke University economics professor Henry Grabowski and his colleagues suggest the Hatch-Waxman statute be revised to mirror biosimilars legislation and provide 12 years of market exclusivity.